Over the course of six months, an AI trading robot for Pfizer (PFE, $38.90) saw a 17% return.
In our robot workshop, this AI trading bot from Swing trader: Downtrend Protection v.2 (TA) was a top performer, generated 17% for PFE over the past six months.
Pfizer (PFE) is a well-known pharmaceutical company with a market capitalization of over $200 billion. Over the past six months, an AI trading robot named Swing trader: Downtrend Protection v.2 (TA) has generated a solid 17% return on PFE. This is a promising result and highlights the potential benefits of utilizing AI and machine learning algorithms to make trading decisions.
However, it is important to note that past performance is not a guarantee of future results. Even with a successful track record, it is crucial to continue monitoring the stock's momentum and any other relevant indicators to ensure that trading decisions are based on the most up-to-date information.
The Momentum Indicator is one such tool that traders can use to gauge the direction of a stock's price movement. On April 18, 2023, PFE's Momentum Indicator moved below the 0 level, which could signal a new downward trend for the stock. This is a cause for concern for traders who may want to consider selling the stock or exploring put options.
To gain a better understanding of how PFE has historically responded to this indicator turning negative, Tickeron's A.I.dvisor analyzed 81 similar instances. The results show that in 50 of these cases, the stock moved further down in the following days. This suggests that there is a 62% chance of a decline in the coming days.
It is important to note that while this information is useful for traders, it is only one piece of the puzzle. Other factors such as earnings reports, news events, and market sentiment can also influence a stock's performance. Therefore, it is crucial to conduct thorough research and analysis before making any trading decisions.
In terms of earnings results, Pfizer recently reported its first-quarter 2023 financial results. The company beat earnings estimates with adjusted earnings per share of $0.98, compared to the expected $0.96. Revenue for the quarter was $16.7 billion, which also exceeded expectations. This positive earnings report may have helped to support PFE's price in the short-term, but traders should continue to monitor the stock's momentum and other relevant indicators for any potential shifts in market sentiment.
Overall, while the AI trading robot's 17% return on PFE over the past six months is an encouraging sign, it is crucial to remain vigilant and continuously analyze relevant indicators to make informed trading decisions.
PFE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 12, 2025
PFE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 44 cases where PFE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where PFE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 230 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on August 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on August 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
PFE moved below its 50-day moving average on September 12, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PFE crossed bearishly below the 50-day moving average on September 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.530) is normal, around the industry mean (9.545). P/E Ratio (12.630) is within average values for comparable stocks, (23.892). Projected Growth (PEG Ratio) (0.956) is also within normal values, averaging (1.752). PFE's Dividend Yield (0.072) is considerably higher than the industry average of (0.028). P/S Ratio (2.134) is also within normal values, averaging (3.442).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PFE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement